PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer
